Estimates of the prevalence and number of fibromyalgia syndrome patients and their alpha-1 antitrypsin phenotypic distribution in ten countries

Journal of Musculoskeletal Pain

Volumn 15, Issue 4, 2007, Pages 9-23

  Blanco, Ignacio ^a   De Serres, Frederick ^b   Janciauskiene, Sabina ^c   Arbesú, Daniel ^a   Fernández Bustillo, Enrique ^d   Cárcaba, Victoriano ^a   Nita, Izabela ^c   Astudillo, Aurora ^d  

^a HOSPITAL VALLE DEL NALÓN   (Spain)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Alpha 1 antitrypsin deficiency; Epidemiological studies; Fibromyalgia syndrome; Fibromyalgia syndrome prevalence

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CANADA; DENMARK; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; FIBROMYALGIA; FINLAND; GENE FREQUENCY; GERMANY; HUMAN; ITALY; MUSCLE BIOPSY; NETHERLANDS; PAKISTAN; PHENOTYPE; PREVALENCE; SPAIN; STATISTICAL ANALYSIS; UNITED STATES;

EID: 34548682068     PISSN: 10582452     EISSN: 15407012     Source Type: Journal    
DOI: 10.1300/J094v15n04_03     Document Type: Article

References (108)

1. Silverman GA, Bird PhI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O'Donnell E, Salvesen GS, Travis J, Whisstock JC: The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276 (36): 33293-33296, 2001.
2. Brantly M, Nukiwa T, Crystal RG: Molecular basis of alpha-1-antitrypsin deficiency. Am J Med 84 (6A): 13-31, 1988.
3. Janciauskiene S: Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochim Biophys Acta 1535(3): 221-235, 2001.
4. Janciauskiene S, Larsson S, Larsson P, Virtala R, Jansson L, Stevens T: Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin. Biochem Biophys Res Commun 321(3): 592-600, 2004.
5. Hadzic R, Nita I, Tassidis H, Riesbeck K, Wingren AG, Janciauskiene S: Alpha1-antitrypsin inhibits Moraxella catarrhalis MID protein-induced tonsillar B cell proliferation and IL-6 release. Immunol Lett 102(2): 141-147, 2006.
6. Nita I, Hollander C, Westin U, Janciauskiene S: Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Respir Res 31 (1): 12-18, 2005.
7. Byth BC, Billingsley GD, Cox DW: Physical and genetic mapping of the serpin gene cluster at 14q32.1: allelic association and a unique haplotype associated with alpha 1-antitrypsin deficiency. Am J Hum Genet 55 (1): 126-133, 1994.
8. De Serres, FJ: Worldwide racial and ethnic distribution of alpha-1 antitrypsin deficiency: Details of an analysis of published genetic epidemiological surveys. Chest 122(5): 818-1829, 2002.
9. Carrell RW, Jeppsson JO, Laurell CB: Structure and variation of human alpha 1-antitrypsin. Nature 298 (5872): 329-334, 1982.
10. Carrell RW, Lomas DA: Alpha-1 antitrypsin deficiency -a model for conformational diseases. N Engl J Med 346 (1): 45-53, 2002.
11. Stoller, JK, Snider GL, Brantly ML: American Thoracic Society/European Respiratory Society statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 168(7): 818-855, 2003.
12. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum 33: 160-172, 1990.
13. Neumann L, Buskila D: Epidemiology of fibromyalgia. Curr Pain Headache Rep 7(5): 362-368, 2003.
14. Bennet R: Fibromyalgia: present to future. Curr Pain Headhache Rep 8: 379-384, 2004.
15. Staud R: Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Current Rheumatol Rep 4:299-305, 2002.
16. Blanco I, Canto H, de Serres FJ, Bustillo EF, Rodríguez MC: Alpha-1-antitrypsin replacement therapy efficiently controls fibromyalgia symptoms in two PI ZZ alpha-1-antitrypsin deficiency patients. J Rheumatol 31(10): 2082-2085, 2004.
17. Blanco I, Janciauskiene S, Astudillo A, Domínguez F, Nita I, Bustillo EF: Fibromyalgia and alpha-1 antitrypsin. New Research on Fibromyalgia. Edited by JA Pederson. Nova Publishers, New York, 2006.
18. Blanco I, Arbesú D, Alkassam D, de Serres J, Bustillo EF, Rodríguez-Menéndez C: Alpha1-antitrypsin polymorphism in fibromyalgia patients from the Asturias Province in Northern Spain: A significantly higher prevalence of the PI*Z deficiency allele in patients than in the general population. J Musculoske Pain 14(3): 5-12, 2006.
19. Blanco IE, de Serres FJ, Fernández-Bustillo E, Kassam DA, Arbesu D, Rodriguez C, Torre JC: Alpha-1 antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. Med Hypotheses 64 (4): 759-769, 2005.
20. MacNally JD, Matheson DA, Bakowsky VS: The epidemiology of self-reported fibromyalgia in Canada. Chronic Dis Can 27(1): 9-16, 2006.
21. White KP, Speechley M, Harth M, Osthye T: The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 26(7):1570-1576, 1999.
22. White KP, Speechley M, Harth M, Osthye T: The London Fibromyalgia Epidemiology Study: comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls. J Rheumatol 26(7):1577-1585, 1999.
23. White KP, Thompson J: Fibromyalgia syndrome in an Amish community: a controlled study to determine disease and symptom prevalence. J Rheumatol 30(8): 1835-1840, 2003.
24. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38(1):19-28, 1995.
25. Wolfe F, Cathey MA: Prevalence of primary and secondary fibrositis. J Rheumatol 10(6): 965-968, 1983.
26. Prescott E, Kjoller M, Jacobsen S, Bulow PM, Danneskiold-Sansoe B, Kamper-Jorgensen F: Fibromyalgia in the adult Danish population: I. A prevalence study. Scand J Rheumatol 22(5):233-237, 1993.
27. Makela M., Heliovaara M: Prevalence of primary fibromyalgia in the Finnish population. BMJ 303 (6796): 216-219, 1991.
28. Raspe H: Rheumatism epidemiology in Europe. Soz Praventivmed. 37(4):168-178, 1992
29. Schochat T, Raspe H: Elements of fibromyalgia in an open population. Rheumatology 42(7): 829-835, 2003.
30. Salaffi F, De Angelis R, Grassi W: Marche Pain Prevalence, Investigation Group Mapping Study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 23(6): 819-828, 2005.
31. Cimmino MA, Zampogna A, Murroni S, Barruffi S, Alessio G, Maio T, Mela GS: Methodology of an epidemiologic prevalence study in rheumatology: the Chiavari study. Reumatismo 54(1): 40-47, 2002.
32. Bazelmans E., Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van Weel C, van der Meer JW, Bleijenberg G: Chronic Fatigue Syndrome and Primary Fibromyalgia Syndrome as recognized by GPs. Fam Pract 16(6): 602-604, 1999.
33. Picavet HSJ, Hazes JMW: Prevalence of self reported musculoskeletal diseases is high. Ann Rheum Dis 62(7): 644-650, 2003.
34. Gamero Ruiz F, Gabriel Sanchez R, Carbonell Abello J, Tornero Molina J, Sanchez Magro I: Pain in Spanish rheumatology outpatient offices: EPIDOR epidemiological study. Rev Clin Esp 205(4):157-163, 2005.
35. Carmona L, Ballina J, Gabriel R, Laffton A: EPISER Study Group. The burden of musculoskeletal diseases in the general population of Spain: Results from a national survey. Ann Rheum Dis 60(11): 1040-1045, 2001.
36. Lindell L, de Jong MP, Osikowicz W, Lazzaroni R, Gerggren M, Salaneck WR, Crispin X: Prevalence of fibromyalgia and chronic widespread pain. Scand J Prim Health Care 18(3):149-153, 2000.
37. Lundberg G, Gerdle B: Tender point scores and their relations to signs of mobility, symptoms, and disability in female home care personnel and the prevalence of fibromyalgia syndrome. J Rheumatol 29(3): 603-613, 2002.
38. Farooqi A, Gibson T: Prevalence of the major rheumatic disorders in the adult population of north Pakistan. Br J Rheumatol 37(5): 491-495, 1998.
39. Haq SA, Darmawan J, Islam MN, Uddin MZ, Das BB, Rahman F, Chowdhury MA, Alam MN, Mahmud TA, Chowdhury MR, Thair M: Prevalence of rheumatic diseases and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study. J Rheumatol 32(2):348-353, 2005.
40. Topbas M, Cakirbay H, Gulec H, Akgol E, Ak I, Can G: The prevalence of fibromyalgia in women aged 20-64 in Turkey. Scand J Rheumatol 34(2):140-144, 2005.
41. Senna ER, De Barros AL, Silva EO, Costa IF, Pereira LV, Ciconelli RM, Feraz MB: Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol 31(3):594-397, 2004.
42. Cardiel MH, Rojas-Serrano J: Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 20(5): 617-624, 2002.
43. Blanco I, Fernández E, Bustillo EF: Alpha-1-antitrypsin PI phenotypes S and Z in Europe: an analysis of the published surveys. Clin Genet 60:31-41, 2001.
44. Blanco I, Bustillo EF, Rodríguez MC: Distribution of a1-antitrypsin PI S and PI Z frequencies in countries outside Europe: a meta-analysis. Clin Genet 60: 431-444, 2001.
45. De Serres FJ, Blanco I, Bustillo EF: Genetic Epidemiology of Alpha-1 antitrypsin Deficiency: France, Italy, Portugal and Spain. Clin Genet 63:1-20, 2003.
46. De Serres, Blanco I., Fernandez-Bustillo E: Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet 64(5):382-397, 2003.
47. Blanco I, de Serres F, Fernandez-Bustillo E, Lara B, Miravitlles M: Estimated numbers and prevalence of PI*S and PI*Z alleles of a1-antitrypsin deficiency in European countries. Eur Respir J 27(1):77-84, 2006.
48. Hardy-Weinberg principle. Wikipedia. Retrieved July 20, 2006 from: http://en.wikipedia.org/wiki/Hardy-Weinberg_principle
49. The World Fact Book. CIA. Retrieved May, 2006 from: http://www.odci.gov/ cia/publications/factbook/index.html
50. Cox DW, Simpsom NE, Jantti R: Group-specific component alpha-1 antitrypsin and esterase D in Canadian Eskimos. Hum Hered 28(5): 341-350, 1978.
51. Singh R, Horne SL, Gerrard JW, De Coteau WE: Alpha-1 antitrypsin phenotypes in Canadian metis. Hum Hered 33: 181-183, 1983.
52. Chan-Yeung M, Ashley MJ, Corey P, Maledy M: Pi phenotypes and the prevalence of chest symptoms and lung function abnormalities in workers employed in dusty industries. Am Rev Respir Dis 117: 239-245, 1978.
53. Talamo RC, Thurlbeck WM: Alpha-1 antitrypsin Pi types in postmortem blood. Am rev Respir Dis 112(2): 201-207, 1975.
54. Ashley J, M Chan-Yeung, Corey PN: Pi phenotypes in North American workers: racial differences and comparisons with reported frequencies. Hum Hered 30(2): 107-111, 1980.
55. Moroz SP, Cutz E, Cox DW, Sass-Kortsak A: Liver disease associated with alpha-1 antitrypsin deficiency in childhood. J Pediatrics 88(1): 19-25, 1976.
56. Joly J, Richer V, Boisvert F, Laverdiere M: Alpha-1 phenotypes in French Canadian newborns. Hum Hered 30:1-2, 1980.
57. Horne SL, Clark ME, Barnett GD: Alpha-1-antrypsin deficiency: Its effect on pulmonary function in Saskatchewan grain buyers. Occupational Pulmonry Disease: Focus on Grain Dust and Health 347-356, 1980.
58. Roberts A, Kagan A, Rhoads GG: Antitrypsin and chronic obstructive pulmonary disease among Japanese-American men. Chest 72(4): 489-491, 1977.
59. Cohen BH, Ball WC Jr., Bias WB: A genetic-epidemiologic study of chronic obstructive pulmonary disease. I. Study design and preliminary observations. Johns Hopkins Med J 137(3): 95-104, 1975.
60. Schwartz RH, Van Ess JD, Johnstone DE: Alpha-1 antitrypsin in childhood asthma. J Allergy Clin Immunol 59(1): 31-34, 1977.
61. Rynbrandt DJ, Ihrig J, Kleinerman J: Serum trypsin inhibitory capacity and Pi phenotypes. I. Methods and control values. Am J Clin Pathol 63(2): 251-260, 1975.
62. Gerblich AA, Kleinerman J, Rynbrandt DJ: Pi-Z phenotypes in a pulmonary clinic. Their prevalence and physiologic state. Am J Clin Pathol 69(5):509-513, 1978.
63. Dykes DD, Miller SA, Polesky HF: Distribution of alpha 1-antitrypsin variants in a US white population. Hum Hered 34(5): 308-310, 1984.
64. Morse JO, Lebowitz MD, Knudson RJ: Relation of protease inhibitor phenotypes to obstructive lung diseases in a community. N Engl J Med 296(21): 1190-1194, 1977
65. Webb DR, Hyde RW, Schwartz RH: Serum alpha 1-antitrypsin variants. Prevalence and clinical spirometry. Am Rev Respir Dis 108(4): 918-925, 1973.
66. Thymann M. Distribution of alpha-1-antitrypsin (Pi) phenotypes in Denmark determined by separator isoelectric focusing in agarose gel. Hum Hered 36: 19-23, 1986.
67. Dahl M, Nordestgaard BG, Lange P, Vestbo J, Tybjaerg-Hansen A: Molecular diagnosis of intermediate and severe alpha-1 antitrypsin deficiency: MZ individuals with chronic obstructive pulmonary disease may have lower lung function than MM individuals. Clin Chem 47(1): 56-62, 2001.
68. Arvilommi H: Studies on serum Pi and C3-polymorphim in Finland. Acta Path Microbiol Scand 234 (Suppl): 1-50, 1972.
69. Fagerhol MK, Eriksson AW, Monn E: Serum Pi types in some Lappish and Finnish populations. Hum Hered 19: 360-364, 1969.
70. Arnaud P, Koistinen J, Wilson GB, Fudenberg HH: Alpha-1 antitrypsin (Pi) phenotypes in a Finish population. Scand J Clin Lab Invest 37: 339-343, 1977.
71. Fagerhol MK, Gedde-Dahl T Jr.: Genetics of the Pi serum types. Family studies of the inherited variants of serum alpha-1 antitrypsin. Hum Hered 19(4): 354-359, 1969.
72. Weidinger S, Schwarzfischer F, Cleve H: Pi subtyping by isoelectric focusing: further genetic studies and application to paternity examinations. Z Rechtsmed 86(1): 1-7, 1980.
73. Weidinger S, Cleve H, Patutschnick W: Alpha-1 antitrypsin: evidence for a fourth PiM allele. Distribution of the PiM subtypes in Southern Germany. Z Rechtsmed 88(3): 203-211, 1982.
74. Genz T, Martin JP, Cleve H: Classification of alpha1-antitrypsin (Pi) phenotypes by isoelectrofocusing. Distinction of six subtypes of the PiM phenotype. Hum Genet 38(3): 325-332, 1977.
75. Schmechta H, Geserick G: Population genetic studies on alpha-1 antitrypsin polymorphism (Pi-system) in the population of Berlin. Deutsche Gesundheitswesen-Zeitschrift Fur Klinische Medizin 27(23): 1089-1091, 1972.
76. Patzelt D, Schroder H: Genetic-polymorphism of alpha-1 antitrypsin (Pi System) -Data on the formal and population-genetics of the Pi subtypes. Deutsche Gesundheitswesen-Zeitschrift Fur Klinische Medizin 38(3): 119-123, 1983
77. Pittschieler K, Massi G: Alpha-1 antitrypsin deficiency in two population groups in north Italy. Paedriatr Padol 23: 307-311,1988.
78. Seefried-Lehmann SJ, Walter H, Danker-Hopfe H, Ricjards O, De Stefano GF: Investigations on the variability of four genetic serum protein markers (HP; TF; CG a nd PI subtypes) in Italy. Z. Morp. Anthrop 79 (2): 215-231, 1992.
79. Massi G, Cotumaccio R, Auconi P: Alpha-1 antirypsin (Alpha-1-AT) phenotypes and PiM subtypes in Italy. Evidence of considerable geographic variability. Hum Genet 61: 76-77, 1982.
80. Piantelli M, Auconi P, Musiani P: Alpha-1-antitrypsin phenotypes in newborns from Central and Southern Italy. Hum Hered 28: 468-473, 1978.
81. Pascali VL, De Mercurio DL: Determination of alpha-1 antitrypsin subtypes in the population of Rome: a study in ultrathin-layer isoelectric focusing. Hum Hered 31: 296-298, 1981.
82. Massi G, Fabiano A, Ragusa D, Auconi P, Biagini R, Farinato MA, Bandelloni R: Alpha-1 antitrypsin phenotypes and Pi M subtypes in Italy. Bull Eur Physiopathol Respir 16 (Suppl.):301-306,1980.
83. Hoffman JJML, van den Broek WGM: Distribution of alpha-1 antitrypsin phenotypes in two Dutch population groups. Hum Genet 32: 43-48, 1976.
84. Klasen EC, Biemond I, Weterman IT: Alpha-1 antitrypsin levels and phenotypes in Crohn's disease in the Netherlands. Gut 21(10): 840-842, 1980.
85. Biedmond I, Shelby WS, Jewell DP: Alpha-1 antitrypsin serum concentration and phenotypes in ulcerative colitis. Digestion 29: 124-128, 1984.
86. Blanco I, Fernández E, Rodríguez MC, Fernandez A: Allelic frequency of the gene of alpha-1-antitrypsin in the general population in a county in Asturias. Med Clin [Barc] 113(10): 366-370, 1999.
87. Vidal R, Miravitlles M, Jardí R, Torrella M, Rodriguez-Frias F, Moral P, Vaque J: Study of the frequency of different phenotypes of alpha-1 antitrypsin in a population of Barcelona. Med Clin (Barc) 107(6): 211-214, 1996.
88. Puertas MJA, Arranz-Peña ML: Alpha-1 antitrypsin phenotypes in a newborns population from Castilla-Leon. Rev Clín Esp 184: 106-108, 1989.
89. Moral P: Estudio antropogenético de diversos polimorfismos hematológicos en la isla de Menorca. Tesis Doctoral. Univ Barcelona, 1986.
90. Hjalmarsson K: Distribution of alpha-1 antitypsin phenotypes in Sweden. Hum Hered 38: 27-30, 1988.
91. Shahid A, Siddiqui AA, Zuberi SJ, Waqar M: Phenotypes of alpha-1 antitrypsin in Karachi, Pakistan. J Pak Med Assoc 59(11): 374-376, 2000.
92. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH: Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumathology 40(7):743-749, 2001.
93. Wallace DJ: Is there a role for cytokine based therapies in fibromyalgia? Curr Pharm Des 12(1):17-22, 2006.
94. Pache M, Ochs J, Genth E, Mierau R, Kube T, Flammer J: Increased plasma endothelin-1 levels in fibromyalgia syndrome. Rheumatology 42: 493-494, 2003.
95. Maes M, Libbrecht I, Van Hunsel F, Lin AH, De Clerck L, Stevens W, Kenis G, de Jongh R, Bosmans E, Neels H: The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Psychoneuroendocrinology 24(4): 371-383, 1999.
96. Pay S, Calgunery M, Caliskaner Z, Dinc A, Apras S, Ertenli I, Kiraz S, Cobankara V: Evaluation of vascular injury with proinflammatory cytokines, thrombomodulin and fibronectin in patients with primary fibromyalgia. Nagoya J Med Sci 63(3-4): 115-122, 2000.
97. Gur A, Karakoc M, Nas K, Remzi, Cevik, Denli A, Sarac J: Cytokines and depression in cases with fibromyalgia. J Rheumatol 29(2): 358-361, 2002.
98. Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ: Regional cerebral flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol 20(6): 753-760, 2002.
99. Hein G, Franke S: Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? Rheumatology 41(10): 1163-1167, 2002.
100. Bagis S, Tamer L, Sahin G, Sahin G, Bilgin R, Guler H, Ercan B, Erdogan C: Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Rheumatol Int 28: 188-190, 2003.
101. Ozgocmen S, Ozyurt H, Sogut S, Akyol O, Ardicoglu O, Yildizhan H: Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int 10: 1-6, 2005.
102. Ozgocmen S, Ozyurt H, Sogut S, Akyol O: Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide. Rheumatol Int 20: 1-13, 2005.
103. Salemi S, Rethage J, Wollina U, Michel BA, Gay RE, Gay S, Sprott H: Detection of Interleukin 1 beta (IL-beta), IL-6, and Tumor Necrosis Factor-alpha in Skin of Patients with Fibromyalgia. J Rheumatol 30(1): 146-150, 2003.
104. Rüster M, Franke S, Späth M, Pongratz DE, Stein G, Hein GE: Detection of elevated N epsilon-carboxymethyllysine levels in muscular tissue and in serum of patients with fibromyalgia. Scand J Rheumatol 34(6): 460-463, 2005.
105. Libert C, Van Molle W, Brouckaert P, Fiers W: Alpha-1 antitrypsin inhibits the lethal response to TNF in mice. J Immunol 157(11): 5126-5129, 1996.
106. Churg A, Wang RD, Xie C, Wright JL: Alpha-1 antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 168(2): 199-207, 2003.
107. Knappstein S, Ide T, Schmidt MA, Heusipp G: Alpha-1 antitrypsin binds to and interferes with functionality of EspB from atypical and typical enteropathogenic Escherichia coli strains. Infect Immun 72(8): 4344-4350, 2004.
108. Aldonyte J, Jansson L, Ljungberg O, Larsson S, Janciauskiene S: Polymerized alpha-antitrypsin is present on lung vascular endothelium. New insights into the biological significance of alpha-antitrypsin polymerization. Histopathology 45(6): 587-592, 2004.